Author

C. M. Perou

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2

Frequent Co-Authors

A. A. Whitman· 1 shared A. Bhattacharya· 1 shared A. F. Olshan· 1 shared A. Kabanov· 1 shared A. Rishi· 1 shared A. Srisuwananukorn· 1 shared A. T. Pearson· 1 shared A. Woodard· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 5 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Whitman

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors

H. Kim, A. A. Whitman, K. Wisniewska, R. T. Kakati, S. Garcia-Recio, B. C. Calhoun, H. L. Franco, C. M. Perou, P. M. Spanheimer

The paper examines tamoxifen response in ER+/HER2- breast tumors at single-cell resolution, identifying resistant subpopulations and their prognostic significance.

bioRxiv · Apr 1, 2023Cancer Biology

High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer

C. Lim, D. Hwang, M. Yazdimamaghani, H. M. Atkins, H. Hyun, Y. Shin, J. D. Ramsey, C. M. Perou, M. Sokolsky-Papkov, A. Kabanov

This study evaluates high-dose paclitaxel and its combination with CSF1R inhibitor in polymeric micelles for chemoimmunotherapy of triple-negative breast cancer, showing improved therapeutic outcomes and immune response.

bioRxiv · Aug 12, 2022Cancer Biology

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence

F. M. Howard, J. Dolezal, S. Kochanny, G. Khramtsova, J. Vickery, A. Srisuwananukorn, A. Woodard, N. Chen, R. Nanda, C. M. Perou, O. I. Olopade, D. Huo, A. T. Pearson

This paper develops a deep learning model that predicts breast cancer recurrence using digital histology and clinical factors, outperforming a clinical nomogram and identifying patients who may avoid genomic testing.

bioRxiv · Jul 7, 2022 · PreprintCancer Biology

Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics

S. Bhatia, M. Kramer, S. Russo, P. Naik, G. Arun, K. Brophy, P. A. Andrews, C. Fan, C. M. Perou, J. Preall, T. Ha, D. Plenker, D. Tuveson, A. Rishi, J. E. Wilkinson, , D. L. Spector

This study develops and characterizes patient-derived TNBC organoids that recapitulate tumor properties and identify key signaling pathways involved in cancer progression.

bioRxiv · Aug 9, 2021Cancer Biology

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

Y. Gao, E. B. Kabotyanski, E. Villegas, J. H. Shepherd, D. Acosta, C. Hamor, T. Sun, C. Montemayor-Garcia, X. He, L. E. Dobrolecki, T. F. Westbrook, M. T. Lewis, S. G. Hilsenbeck, X. H.- F. Zhang, C. M. Perou, J. M. Rosen

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

bioRxiv · Jun 16, 2021Cancer Biology

A framework for transcriptome-wide association studies in breast cancer in diverse study populations

A. Bhattacharya, M. Garcia-Closas, A. F. Olshan, C. M. Perou, M. A. Troester, M. I. Love

This paper develops a framework for transcriptome-wide association studies (TWAS) in breast cancer across diverse populations, identifying gene associations in underrepresented groups that are missed by GWAS.

bioRxiv · Sep 14, 2019Cancer Biology

A class of GATA3 mutation reprograms the breast cancertranscriptional network through gain and loss of function

M. Takaku, S. A. Grimm, J. D. Roberts, K. Chrysovergis, B. D. Bennett, P. Myers, L. Perera, C. J. Tucker, C. M. Perou, P. A. Wade

This study shows that some GATA3 mutations in breast cancer cause both loss and gain of function, altering the transcriptional network.

bioRxiv · Oct 16, 2017Cell Biology